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Abstract
Numerous studies by our lab and others demonstrate that epidermal growth factor receptor (EGFR) plays critical
roles in primary breast cancer (BC) initiation, growth and dissemination. However, clinical trials targeting EGFR
function in BC have lead to disappointing results. In the current study we sought to identify the mechanisms
responsible for this disparity by investigating the function of EGFR across the continuum of the metastatic
cascade. We previously established that overexpression of EGFR is sufficient for formation of in situ primary
tumors by otherwise nontransformed murine mammary gland cells. Induction of epithelial-mesenchymal transition
(EMT) is sufficient to drive the metastasis of these EGFR-transformed tumors. Examining growth factor receptor
expression across this and other models revealed a potent downregulation of EGFR through metastatic
progression. Consistent with diminution of EGFR following EMT and metastasis EGF stimulation changes from a
proliferative to an apoptotic response in in situ versus metastatic tumor cells, respectively. Furthermore,
overexpression of EGFR in metastatic MDA-MB-231 BC cells promoted their antitumorigenic response to EGF in
three dimensional (3D) metastatic outgrowth assays. In line with the paradoxical function of EGFR through EMT
and metastasis we demonstrate that the EGFR inhibitory molecule, Mitogen Induced Gene-6 (Mig6), is tumor
suppressive in in situ tumor cells. However, Mig6 expression is absolutely required for prevention of apoptosis and
ultimate metastasis of MDA-MB-231 cells. Further understanding of the paradoxical function of EGFR between
primary and metastatic tumors will be essential for application of its targeted molecular therapies in BC.
Neoplasia (2015) 17, 124–133

Abbreviations: Mig6, mitogen-induced gene-6; BC, breast cancer; EGFR, epidermal
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Introduction
Epidermal growth factor receptor (EGFR) is a well-established
proto-oncogene. Indeed, we demonstrated that the overexpression of
EGFR is capable of transforming mammary epithelial cells, and that
transforming growth factor β (TGF-β)–mediated epithelial-mesenchymal
transition (EMT) in concert with EGFR facilitates primary mammary
tumor cell invasion and dissemination [1,2]. Along these lines, primary
breast tumors expressing elevated levels of EGFR display decreased
clinical prognosis [3]. These and other findings point to the targeting of
EGFR as an effective means by which to combat breast cancer (BC)
metastasis. However, the clinical application of EGFR-targeting agents to
treat BC has been largely unsuccessful [4–6]. The molecular mechanisms
that underlie this inherent resistance of BC to EGFR-targeted therapies
remain undefined.
An emerging topic in the field of EGFR signaling is the role of
inhibitory proteins that function to mitigate signaling following EGFR
activation. One such protein is Mitogen Inducible Gene-6 (Mig6), also
known as receptor-associated late transducer (RALT), Gene33, or ErbB
receptor feedback inhibitor (ERRFI). Cells utilize Mig6 and other
feedback inhibitory molecules to balance physiological signaling
emanating from EGFR in terms of both time and intensity [7].
Mechanistically, Mig6 binds to the intracellular domain of EGFR via its
EGFR binding Region (EBR) and inhibits downstream signaling to
various effector molecules such as Erk1/2 and Akt [8,9]. Furthermore,
Mig6 is genetically altered and transcriptionally silenced in lung cancer,
a cancer that can be driven by constitutive activation of EGFR [9].
Genetic deletion of Mig6 results in tumor formation in mice due to
hyper-activation of EGFR [10]. Finally, in addition to EGFR, Mig6 has
more recently been shown to bind to and facilitate c-Abl nuclear
translocation leading to induction of apoptosis [11].
While the studies referenced above point to Mig6 as a growth
inhibitory, pro-apoptotic and overall tumor suppressive molecule,
contrasting studies have demonstrated its function in tumor progression
and inhibition of apoptosis. For instance, several breast cancer cell lines
express high levels of Mig6 and overexpression of Mig6 in MCF-7 BC
cells inhibits thier apoptosis [12]. Similarly, while genetic depletion of
Mig6 does lead to hyperplasia in several organs it is also associated with
enhanced apoptosis in endothelial cells [13]. Correspondingly,
depletion of the Mig6 in bronchiolar epithelial cells does lead to
increased cell proliferation, but similar measures in endothelial cells
leads to apoptosis [13]. Along these lines, EGF stimulation can induce
apoptosis in EGFR-amplified BC cells [14–17]. We recently established
that EGFR expression is diminished in fully metastatic BC cells as
compared to their systemically invasive but dormant counterparts, and
loss of high level EGFR expression can be brought about during
recovery from TGF-β–induced epithelial-mesenchymal transition
(EMT) [18]. Thus, the precise role of Mig6 and its regulation of pro
versus antitumorigenic EGFR signaling during BC metastasis remain
incompletely understood.
In the current study we delineate a paradoxical shift in EGFR
function through the metastatic progression of BC. Using recombinant
gene overexpression we clearly demonstrate that Mig6 acts as a tumor
suppressor in EGFR-driven in situ mammary tumors. In contrast,
interrogating several models of metastatic progression and clinical
datasets uniformly indicate that as BCs progress from in situ to
metastatic disease, EGFR expression is diminished. Consistent with an
antitumorigenic function of EGFR during late-stage metastatic
progression, overexpression of EGFR or depletion of Mig6 in
MDA-MB-231 cells promoted their apoptosis and dramatically
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reduced their outgrowth in 3D culture and formation of pulmonary
tumors in mice. Collectively, our data delineate a paradoxical shift in
EGFR function through the metastatic progression of BC. These
findings demonstrate a plausible mechanism to explain the inherent
resistance of metastatic BC to EGFR-targeted therapies.
Materials and Methods

Cell lines and Cell Culture
Murine NMuMG, human MDA-MB-231, and human
MDA-MB-468 cells were purchased from ATCC and cultured as
described previously [2,19]. Construction of NMuMG cells expressing
human wild type (WT)-EGFR (NME) and their metastatic variants are
described elsewhere [1,2]. Cellular depletion of Mig6 in MDA-MB-231
was accomplished by VSVG lentiviral transduction of pLKO.1 shRNA
vectors as previously described (Thermo Scientific), sequences of
shRNAs can be found in Supplementary Table 1 [2]. The human
MCF10A parental cell line and its increasingly tumorigenic variants
T1k, Ca1h and Ca1a were kindly provided by Dr. Fred Miller (Wayne
State University) and were cultured as described previously [20]. A list
of the chemical inhibitors used throughout the study can be found in
Supplementary Table 2.

Immunoblotting and Immunofluorescent Analyses
For immunoblot assays, equal aliquots of total cellular protein were
resolved by SDS-PAGE and transferred to PVDF membranes using
standard methods as described [21]. Immunofluorescent assays were
conducted using primary antibodies in combination with a biotinylated
secondary antibodies (Jackson) and Texas-Red conjugated avidin
(Vector) as described [1]. Antibody concentrations and suppliers are
listed in Supplementary Table 3.

Cell Biological Assays

DNA synthesis was measured by [ 3H]thymidine incorporation as
previously described [18]. Caspase 3/7 activity was quantified using the
Caspase 3/7 Glo reagent (Promega) according to the manufacturer’s
instructions. Visualization of the actin cytoskeleton was perform by
staining fixed cells with FITC-conjugated Phalloidin according to the
manufactures instructions (Thermo Scientific).

Three-Dimensional (3D) Organotypic Growth Assays

Ninety-six well plates were coated with Cultrex (50 μl/well) and cells
were resuspended in DMEM supplemented with 10% FBS and 4%
Cultrex (150 μl/well). Luciferase-expressing cells were seeded at a
density of 1 × 10 3 cells/well. Media containing the indicated inhibitors
or growth factors was replaced every 4 days and organoid outgrowth was
detected by the addition of D-luciferin potassium salt (Gold
Biotechnology) to induce bioluminescence, which was quantified
using a GloMax-Multi detection system (Promega).

Tumor Growth and Metastasis Analysis
Orthotopic NME tumors were established and tumor volume was
quantified as previously described [2]. Pulmonary tumor development
was assessed by injection of parental (scrambled shRNA) and
Mig6-deficient cells into the lateral tail vein of nu/nu mice (1 × 10 6
cells/mouse). Where indicated tumor growth and metastasis was
monitored by in vivo bioluminescent imaging as previously described
[1,2,18,20,22]. Bioluminescent images were captured on a Xenogen
IVIS-200 (PerkinElmer). All animal procedures were performed in
accordance to protocols approved by the Institutional Animal Care and
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Use Committee for Case Western Reserve University (Cleveland, OH)
and Purdue University (West Lafayette, IN).

In Silico Analyses
The Cancer Cell Line Encyclopedia contains a repository of log2
expression data derived from Affymetrix U133+2.0 Arrays for 947
unique human cancer cell lines. GEO Dataset GSE3744 contains
expression data using the Affymetrix U133+2.0 for clinical samples
classified as basal-like and non-basal-like [23]. This dataset was analyzed
using the NCBI curated dataset browser tool. The TCGA [24] dataset
was accessed via cBioPortal and analyzed using R.

Statistical Analyses
Statistical analyses were carried out using an unpaired Student’s
T-test. P values b 0.05 were considered statistically significant. P values
for all experiments are indicated. Correlation coefficients and P values
were generated using Prizm-Graph Pad.

Neoplasia Vol. 17, No. 1, 2015
Results

Mig6 is Tumor Suppressive in an EGFR-Driven In Situ Model
of Breast Cancer
Mig6 has previously been described as a tumor suppressor [10],
findings that are contingent upon EGFR acting as a protumorigenic
molecule. To verify the ability of Mig6 to suppress EGFR-induced
tumorigenesis, we sought to heterologously overexpress Myc-tagged
Mig6 constructs in our in situ model of normal murine mammary gland
(NMuMG) cells transformed by overexpression of EGFR (referred to
here as NME cells) (Figure 1A). Importantly, expression of these
constructs did not appreciably affect EGFR levels in our recombinant
system (Figure 1A). However, when these cells were cultured on 2D
plastic substrates under a mixture of extracellular matrix, expression of
the EGFR-binding region (EBR) or WT Mig6 decreased the formation
of filopodia (arrows), an event we have previously attributed to the
function of EGFR in these cells (Figure 1B; [25]). Furthermore, when
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and Mig6-EBR (EBR) primary tumor excised from mice 50 days after engraftment. (G) Mean and SE of wet weights of tumors shown in
panel F, P value is indicated.
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these cells were cultured under 3D organotypic conditions expression of
EBR and WT Mig6 significantly enhanced the formation of hollow,
acinar structures, characteristic of normal mammary epithelial cells
(Figure 1, B and C). Furthermore, expression of EBR and WT Mig6
decreased the ability of EGF to induce phosphorylation of EGFR at
Y845 (Figure 1D). We recently demonstrated that the ability of EGFR
to transform NMuMG cells is dependent upon downstream activation
of Stat3 [19]. Importantly, this critical signaling event was potently
inhibited by expression of EBR and WT Mig6 (Figure 1D). To focus
specifically on the ability of the EGFR-directed function of Mig6 to
inhibit tumor initiation we engrafted the NME cells expressing GFP or
Mig6-EBR onto the fat pad of mice and primary tumor formation was
monitored by caliper measurements (Figure 1E). Mig-EBR dramatically
reduced the ability of NME cells to form primary tumors (Figure 1, F
and G). Collectively, these findings indicate that EGFR-initiated
tumorigenesis can be normalized by the inhibitory actions of Mig6.

Metastatic Breast Cancer Cells Become Inherently Resistant to
Targeted Inhibition of EGFR
NME tumors can be driven to metastasize by a transient induction of
EMT via treatment with TGF-β1 prior to allograft onto the mammary
fat pad [2]. Isolation of the resulting pulmonary metastases yielded the
highly aggressive NME-LM cell line. This cell line undergoes robust
primary tumor formation and spontaneous pulmonary metastasis upon
mammary fat pad engraftment, independent of TGF-β pretreatment
[2]. Isolation of these resultant pulmonary metastases yielded the
NME-LM2 cell line. These isogenic cell lines now constitute a
progression series of cells ranging from nontransformed (NMuMG) to
carcinoma in situ (NMuMG cells transformed by EGFR overexpression, NME) to highly metastatic (NME-LM and NME-LM2) [2].
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Given the ability of Mig6-EBR to prevent NME tumor formation we
next sought to verify inhibition of primary tumor development via
pharmacological inhibition of EGFR. Indeed, similar to expression of
Mig6-EBR, daily oral administration of Erlotinib (50 mg/kg) to mice
bearing orthotopic NME cell engraftments dramatically reduced tumor
formation (Figure 2, A, C and D). In line with our previous report, no
tumor recurrence or metastases were observed by these cells irrespective
of EGFR-directed therapy (Figure 2A; [2]). In stark contrast to the
NME cells, tumor formation by the NME-LM cells (described above)
was only minimally delayed by Erlotinib treatment (Figure 2B), and no
significant differences were observed in primary tumor weight at the
time of primary tumor excision (Figure 2E). Also, following primary
tumor excision, NME-LM tumor recurrence was actually enhanced by
Erlotinib treatment (Figure 2B). Consistent with the role of EGFR in
primary tumor cell dissemination [1,26], pulmonary dissemination of
NME-LM cells was delayed by Erlotinib (Figure 2F), but at the time of
necropsy robust pulmonary metastases were observed in NME-LM
tumor bearing mice irrespective of treatment (Figure 2G). Taken
together, these data strongly suggest that through the processes of
EMT and metastasis even BC cells whose initial transformation is
driven by EGFR are capable of inherently developing resistance to
EGFR-targeted therapy.
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diminished following withdrawal of exogenous TGF-β1 [18]. To
examine this phenomenon in vivo, we conducted single cell analysis of
cell surface EGFR levels in cells subcultured from control (NS) or

TGF-β1 pretreated NME primary tumors. Figure 3A shows flow
cytometry using an antibody specific for the human EGFR transgene
(Figure 3A). These two ex vivo primary tumors displayed similar EGFR
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profiles barring a small population of EGFR-negative cells that was only
detectable in the TGF-β1 pretreated NME tumors (Figure 3A). In
contrast to our in vitro data fluorescence-activated cell sorting for this
ex vivo EGFR (-) population yielded a very mesenchymal cell population
(Figure 3A; inset) that failed to thrive when cultured alone.
Immunofluorescent staining verified the presence of a highly
mesenchymal population of cells that lacked expression of Ecad and
displayed a very filamentous actin cytoskeleton (Figure 3B). More
importantly, although resistant to puromycin, EGFR was undetectable
in this mesenchymal cell population (Figure 3B). Similar comparison of
cell surface EGFR levels between the parental NME cells and their
metastatic and isogenic NME-LM counterparts also displayed a marked
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for expression of EGFR and Mig6. Actin served as a loading control.
(C) The murine NME progression series was analyzed by immunoblot
for the expression EGFR and Mig6 under nonstimulated conditions
(−) and following a 48 hour treatment with TGF-β1 (5 ng/ml). Data in
A-C are representative of at least 3 independent experiments yielding
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reduction in cell surface EGFR levels (Figure 3C). Analysis of total and
phosphorylated levels of EGFR similarly revealed a marked diminution
in the NME-LM cells as compared to their parental NME cells
(Figure 4D, F). Given that EGFR is recombinantly overexpressed in the
NME system we sought to identify possible mechanisms of negative
selection that could be altering the observed EGFR expression levels in
NME-LM cells. Consistent with a negative selection against high level
EGFR expression, prolonged stimulation of NME-LM cells with
exogenous EGF results in apoptosis (Figure 3D) and drastic inhibition
of outgrowth when cultured under 3D organotypic conditions
(Figure 3E). These findings contrast sharply with those obtained in
the parental NME cell line in which apoptosis and growth inhibition
results upon treatment with the EGFR inhibitor AG1478 (Figure 3D
and E). Furthermore, the maintenance of 3D growth of the NME-LM
cells in the presence of AG1478 (Figure 3E) is consistent with our
in vivo data (Figure 2), as well as with the clinical inability of
EGFR-targeted therapies to effectively treat metastatic BC [4].
To verify that diminution of EGFR is not an artifact of our
overexpression system, we assessed EGFR expression across the human
MCF-10A BC progression series. Consistent with the results of our
NME progression series, the fully metastatic MCF-Ca1a cells expressed
very little EGFR (Figure 4A). Consistent with our previous studies in
the NME cells, endogenous EGFR expression was not affected upon
in vitro TGF-β1 stimulation of the MDA-MB-231, but was markedly
lower in ex vivo cells that had metastasized from the mammary fat pad to
axillary lymph nodes and lungs (Figure 4B). Expression of Mig6
mirrored that of EGFR and was similarly diminished in increasingly
metastatic BC cells (Figure 4, A and B). Consistent with the notion that
EGFR and Mig6 expression levels track together, the slight increase in
EGFR expression observed in the NME-LM2 cells as compared to the
NME-LM cells correlated with a corresponding increase in Mig6
(Figure 4C). Furthermore, Mig6 is maintained upon TGF-β treatment
of the NME-LM2 cells, which is contrast to their nonmetastatic
counterparts in which Mig6 is decreased during TGF-β-induced EMT
(Figure 4C). The precise mechanisms that lead to the paradoxical
function and diminution of EGFR following EMT and metastasis are
likely to be highly complex. Nevertheless, our data clearly indicate
that the processes of metastasis support the inherent resistance of BC
to EGFR-targeted therapies via a shift in EGFR signaling from proto antitumorigenic.

There is a Direct Relationship Between EGFR and Mig6
Expression in Basal-Like Breast Cancer
To expand our findings beyond our in vitro model systems we sought
to further examine the regulation of EGFR and Mig6 in clinical BC
samples. Therefore, we analyzed the TCGA BC dataset for the
expression relationship between EGFR and Mig6 [24]. Consistent with
our findings in Figure 4, there was a significant direct correlation
between EGFR and Mig6 expression (Figure 5A). Next, we analyzed
the GEO data set GSE3744 in which patient BCs are classified as basal
like and non-basal like as characterized by microarray analysis [23].
Consistent with EGFR being a major defining factor of basal-like BC
[27] and there being a direct correlation between EGFR and Mig6,
Mig6 expression was significantly higher in this more aggressive subtype
(Figure 5B). Finally, we analyzed the cell line encyclopedia (CCLE) to
establish the ratio of Mig6 to EGFR across the 58 available BC cell lines
(Figure 5C). This analysis indicated that similar to the clinical datasets
there is a robust direct relationship between Mig6 and EGFR expression
(Figure 5C). Two basal-like cell lines, the MDA-MB-231 (MDA-231)
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Figure 5. Expression of Mig6 and EGFR are directly related and required at a balanced ratio for basal-like BC survival in response to EGF. (A)
Analysis of the TCGA BC data set comparing expression of Mig6 versus EGFR. (B) Geo data set GSE3744 was analyzed for expression levels of
Mig6 between non basal-like and basal-like BCs. Data are the Mig6 expression values for individual patient samples resulting in the indicated
means (±SE) and P value. (C) Expression levels of EGFR in relation to Mig6 across 58 human BC cell lines recorded in the CCLE database. The
data points for MDA-MB-231 and MDA-MB-468 cells are noted. (D) MDA-MB-231 and MDA-MB-468 were treated with the indicated
concentrations of EGF for 48 hours and DNA synthesis was quantified by 3H Thymidine incorporation. Data are the mean (±SE) of at least 2
independent experiments carried out in triplicate where * indicates a P ≤ .01. (E) MDA-MB-231 cells were stably constructed to overexpress
EGFR or YFP as a control. Phosphorylation of EGFR in response to EGF as well total expression of EGFR and Mig6 were analyzed by western
blot. Actin served as a loading control. (F) Control (YFP) and EGFR overexpressing MDA-MB-231 cells were cultured under 3D growth
conditions in the presence or absence of EGF (50 ng/ml) for 11 days and 3D outgrowth was quantified by bioluminescence. Data are the mean
of three independent experiments conducted in triplicate resulting in the indicated P values.

and the EGFR-amplified MDA-MB-468 (MDA-468) cells expressed
the second highest and lowest Mig6/EGFR expression ratio,
respectively. In contrast to the MDA-231 cells, EGF stimulation of
the MDA-468 cells is known to induce apoptosis [14]. Along these
lines, EGF stimulation results in a progressive decrease in [ 3H]
Thymidine incorporation in the MDA-468 cells, but not in the
MDA-231 cells (Figure 5D). In an attempt to manipulate the Mig6/
EGFR ratio in the MDA-231 cells we overexpressed EGFR (Figure 5E).
However, consistent with all of the correlative data above, recombinant
overexpression of EGFR in the MDA-231 cells lead to a concomitant
increase in Mig6 expression levels (Figure 5E). These data support our
conclusion that there is a direct relationship between expression levels of
EGFR and Mig6 in metastatic BC (Figure 5E). Finally, outgrowth of
the MDA-231 cells under 3D pulmonary organotypic conditions
confirmed an antitumorigenic effect of EGF in these metastatic BC
cells, a result that was significantly enhanced upon overexpression of
EGFR (Figure 5F).

Mig6 is Required for the Metastatic Outgrowth of MDA-MB231 Cells
Our findings in Figure 5 suggest that the 3D outgrowth inhibitory
effects of EGFR may be partially masked in MDA-231 cells upon
EGFR overexpression due to concomitant upregulation of Mig6

(Figure 5E). To identify the role of Mig6 in empowering metastatic BCs
with the ability to subvert growth inhibitory EGFR signaling, we
utilized shRNAs to specifically deplete Mig6 in the MDA-231 cells
(Figure 6A). Consistent with our previous data in Figures 4 and 5,
depletion of Mig6 using two independent shRNAs led to a
corresponding decrease in EGFR levels, however receptor levels were
still readily detectable in these cells (Figure 6A). Depletion of Mig6
dramatically inhibited the 3D-outgrowth of MDA-231 cells independent of addition of exogenous EGF (Figure 6B and C). Examination of
these 3D cultures revealed the appearance of several apoptotic bodies
(arrows, Figure 6B). This observation was verified by increased levels of
Caspase3/7 activity in Mig6-depleted MDA-231 cells as compared to
their control scrambled shRNA-expressing counterparts (Figure 6D).
Consistent with increased levels of apoptosis, we found that MDA-231
cells lacking Mig6 expression immediately failed to thrive within the
pulmonary microenvironment after being injected into the lateral tail
vein mice (Figure 6, E and F), thereby dramatically inhibiting the
formation of pulmonary tumors by Mig6-deficient MDA-231 cells as
compared to their Mig6 proficient counterparts (Figure 6, E–G).
Discussion
The current study delineates the evolution of EGFR function over the
metastatic progression of BC. Our previous studies demonstrate the
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transforming capabilities of EGFR overexpression in mammary
epithelial cells and the ability of EMT to drive EGFR-mediated
invasion and dissemination [1]. However, our findings herein have gone

on to establish a proapoptotic switch in EGFR function in the later
stages of metastatic outgrowth, a process that can be regulated by
corresponding expression of Mig6.
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The notion that EGFR can play an anti-tumorigenic role in late-stage
BC is supported by our recent study in which we observed loss of EGFR
expression in metastatic outgrowth proficient D2.A1 BC cells as
compared to their invasive but systemically dormant D2.OR
counterparts [18]. We also previously demonstrated the progressive
loss of EGFR expression in the NME cells during in vitro recovery from
TGF-β-induced EMT [18]. This progressive down-regulation of EGFR
during oncogenic mesenchymal-epithelial transition (MET) is further
supported herein by our data utilizing the MCF-10A progression series
where EGFR expression is diminished in Ca1a cells as compared to their
Ca1h counterparts. Indeed, separate studies demonstrate a MET
reaction characterizes the metastatic progression of these two cell lines
[28]. Along these lines, EGFR is undetectable in the highly metastatic
4T1 model of BC (unpublished observation), a cell line we have recently
characterized to undergo EMT:MET reactions during tumor growth
and metastasis [2]. The importance of this bifurcated expression of
EGFR is born out by clinical data that indicate BCs expressing very high
or low levels of EGFR have similarly poorer outcomes as compared to
BCs expressing intermediate levels of EGFR [29]. Our findings herein
expand upon these primary tumor-derived data to suggest that even
high-level EGFR expression is diminished during formation of the
metastatic lesion. These data are consistent with clinical findings that have
demonstrated dowregulation of EGFR2 (Her2) in metastatic versus
primary tumors [30]. Whether this discordance in receptor expression
results due active downregulation of EGFR expression or selection of a
preexisting EGFR low subpopulation remains to be established.
In addition to depletion of EGFR, our data in Figures 4 and 5 suggest
that metastatic BCs can also neutralize EGFR-driven apoptosis via
Mig6. This exciting finding is contrasted sharply by the widely assumed
notion that Mig6 functions solely as a tumor suppressor, a supposition
that holds to the idea that EGFR signaling universally functions in an
oncogenic manner [10,31]. However, it should be noted that several
recent studies have established the ability of EGFR to induce apoptosis
in BCs [15–17,32], while others have established the ability of Mig6 to
protect human BC cells from apoptosis [33]. Indeed, genetic
inactivation of Mig6 results in pulmonary endothelial cell apoptosis
[13]. Likewise, a recent study demonstrated that EGF-induced
apoptosis in MDA-468 cells, which scored the lowest Mig6:EGFR
ratio in our 58 cell line analysis, occurs upon EGFR internalization [17].
Therefore, it is tempting to speculate that unbalanced expression levels
of Mig6 with relation to EGFR leads to unabated activation of
internalized EGFR, initiating a pro-apoptotic event. Why this does not
occur in normal and premalignant cells in which overexpression of
EGFR is strictly protumorigenic is a subject currently under
investigation in our laboratory.
In summary, our study has delineated a paradoxical shift in which the
potent growth promoting properties of EGFR are converted to
antitumorigenic mechanisms during the later stages of metastatic
progression. Furthermore, we show that the antitumorigenic properties
of EGFR in metastatic BC cells are held at bay by the EGFR inhibitory
molecule Mig6. This EGFR paradox presents a plausible explanation
for the inherent resistance of metastatic BC to EGFR-targeted therapies.
Understanding the evolution in EGFR and other RTK signaling across
the metastatic cascade will be essential for the proper application of their
respective targeted therapies for the treatment of metastatic BC.
Acknowledgements
The authors would like to thank members of the Wendt laboratory for
their critical reading of this manuscript. Research support was provided

Neoplasia Vol. 17, No. 1, 2015
in part by the National Institutes of Health (CA166140) to M.K.W; the
National Institutes of Health (GM081498) to C.R.C.; the National
Institutes of Health (CA129359 and CA177069) to W.P.S.; and a
National Institutes of Health (T32 HL007653) to N.B. We also
acknowledge the expertise of the personnel within the Case
Comprehensive Cancer Center (NIH project P30 CA043703) and
the Purdue University Center for Cancer Research (NIH project P30
CA023168) small animal imaging core facilities.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.11.009.
References
[1] Wendt MK, Smith JA, and Schiemann WP (2010). Transforming growth factorbeta-induced epithelial-mesenchymal transition facilitates epidermal growth
factor-dependent breast cancer progression. Oncogene 29(49), 6485–6498.
[2] Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, and Schiemann WP
(2014). Fibroblast growth factor receptor splice variants are stable markers of
oncogenic transforming growth factor- beta1 signaling in metastatic breast
cancers. Breast Cancer Res 16(2), R24.
[3] Tischkowitz M, Brunet J-S, Begin L, Huntsman D, Cheang M, Akslen L,
Nielsen T, and Foulkes W (2007). Use of immunohistochemical markers can
refine prognosis in triple negative breast cancer. BMC Cancer 7(1), 134.
[4] Dickler MN, Cobleigh MA, Miller KD, Klein PM, and Winer EP (2009).
Efficacy and safety of erlotinib in patients with locally advanced or metastatic
breast cancer. Breast Cancer Res Treat 115(1), 115–121.
[5] Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J,
Yeh B, and Lake DE, et al (2008). A phase II trial of erlotinib in combination
with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 14
(23), 7878–7883.
[6] Tredan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J,
Hardy-Bessard AC, and Arance A, et al (2014). Ixabepilone Alone or With
Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative
Breast Cancer. Clin Breast Cancer [pii: S1526-8209(14)00162-1].
[7] Segatto O, Anastasi S, and Alema S (2011). Regulation of epidermal growth factor
receptor signalling by inducible feedback inhibitors. J Cell Sci 124(Pt 11), 1785–1793.
[8] Anastasi S, Baietti MF, Frosi Y, Alema S, and Segatto O (2007). The
evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of
the EGFR catalytic activity. Oncogene 26(57), 7833–7846.
[9] Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B, Resau J, Sigler R, and
Bronson R, et al (2007). Evidence that MIG-6 is a tumor-suppressor gene.
Oncogene 26(2), 269–276.
[10] Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K,
Sommergruber W, Kraut N, and Ullrich A, et al (2006). Mig6 is a negative
regulator of EGF receptor-mediated skin morphogenesis and tumor formation.
Nat Med 12(5), 568–573.
[11] Hopkins S, Linderoth E, Hantschel O, Suarez-Henriques P, Pilia G, Kendrick
H, Smalley MJ, Superti-Furga G, and Ferby I (2012). Mig6 is a sensor of EGF
receptor inactivation that directly activates c-Abl to induce apoptosis during
epithelial homeostasis. Dev Cell 23(3), 547–559.
[12] Xu J, Keeton AB, Wu L, Franklin JL, Cao X, and Messina JL (2005). Gene 33
inhibits apoptosis of breast cancer cells and increases poly(ADP-ribose)
polymerase expression. Breast Cancer Res Treat 91(3), 207–215.
[13] Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, Yang Y, Kurie JM, Yen R, and
Evans CM, et al (2009). Mig-6 is required for appropriate lung development and
to ensure normal adult lung homeostasis. Development 136(19), 3347–3356.
[14] Ettenberg SA, Rubinstein YR, Banerjee P, Nau MM, Keane MM, and Lipkowitz
S (1999). cbl-b inhibits EGF-receptor-induced apoptosis by enhancing
ubiquitination and degradation of activated receptors. Mol Cell Biol Res Commun
2(2), 111–118.
[15] Hyatt DC and Ceresa BP (2008). Cellular localization of the activated EGFR
determines its effect on cell growth in MDA-MB-468 cells. Exp Cell Res 314(18),
3415–3425.
[16] Reinehr R and Haussinger D (2012). CD95 death receptor and epidermal
growth factor receptor (EGFR) in liver cell apoptosis and regeneration. Arch
Biochem Biophys 518(1), 2–7.

Neoplasia Vol. 17, No. 1, 2015
[17] Rush JS, Quinalty LM, Engelman L, Sherry DM, and Ceresa BP (2012).
Endosomal accumulation of the activated epidermal growth factor receptor
(EGFR) induces apoptosis. J Biol Chem 287(1), 712–722.
[18] Wendt MK, Taylor MA, Schiemann BJ, and Schiemann WP (2011). Downregulation of epithelial cadherin is required to initiate metastatic outgrowth of
breast cancer. Mol Biol Cell 22(14), 2423–2435.
[19] Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP, and Carlin CR
(2013). Epithelial-to-Mesenchymal Transition Promotes Breast Cancer Progression via a Fibronectin-Dependent Stat3 Signaling Pathway. J Biol Chem 288(25),
17954–17967.
[20] Wendt MK, Smith JA, and Schiemann WP (2009). p130Cas is required for
mammary tumor growth and transforming growth factor-beta-mediated metastasis
through regulation of Smad2/3 activity. J Biol Chem 284(49), 34145–34156.
[21] Wendt M and Schiemann W (2009). Therapeutic targeting of the focal adhesion
complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer
Res 11(5), R68.
[22] Wendt MK, Schiemann BJ, Parvani JG, Lee YH, Kang Y, and Schiemann WP
(2013). TGF-beta stimulates Pyk2 expression as part of an epithelialmesenchymal transition program required for metastatic outgrowth of breast
cancer. Oncogene 32(16), 2005–2015.
[23] Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X,
Iglehart JD, and Livingston DM, et al (2006). X chromosomal abnormalities in
basal-like human breast cancer. Cancer Cell 9(2), 121–132.
[24] TCGA (2012). Comprehensive molecular portraits of human breast tumours.
Nature 490(7418), 61–70.
[25] Balanis N, Yoshigi M, Wendt MK, Schiemann WP, and Carlin CR (2011).
beta3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse
mammary gland epithelial cells. Mol Biol Cell 22(22), 4288–4301.

An EGFR Paradox in Metastatic Breast Cancer

Wendt et al.

133

[26] Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW,
and Segall J, et al (2004). A Paracrine Loop between Tumor Cells and
Macrophages Is Required for Tumor Cell Migration in Mammary Tumors.
Cancer Res 64(19), 7022–7029.
[27] Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM,
and Nielsen TO (2008). Basal-like breast cancer defined by five biomarkers has
superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5),
1368–1376.
[28] Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, Mercatali
L, Khan Z, and Goodarzi H, et al (2011). Direct targeting of Sec23a by miR200s influences cancer cell secretome and promotes metastatic colonization. Nat
Med 17(9), 1101–1108.
[29] Kreike B, Hart G, Bartelink H, and van de Vijver MJ (2010). Analysis of breast
cancer related gene expression using natural splines and the Cox proportional
hazard model to identify prognostic associations. Breast Cancer Res Treat 122(3),
711–720.
[30] Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y,
Gonzalez-Angulo AM, and Hortobagyi GN, et al (2012). Loss of human
epidermal growth factor receptor 2 (HER2) expression in metastatic sites of
HER2-overexpressing primary breast tumors. J Clin Oncol 30(6), 593–599.
[31] Hackel PO, Gishizky M, and Ullrich A (2001). Mig-6 is a negative regulator of
the epidermal growth factor receptor signal. Biol Chem 382(12), 1649–1662.
[32] Armstrong DK, Kaufmann SH, Ottaviano YL, Furuya Y, Buckley JA, Isaacs JT,
and Davidson NE (1994). Epidermal growth factor-mediated apoptosis of
MDA-MB-468 human breast cancer cells. Cancer Res 54(20), 5280–5283.
[33] Xu D, Makkinje A, and Kyriakis JM (2005). Gene 33 is an endogenous inhibitor
of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J Biol Chem 280(4), 2924–2933.

